SITC 2021 | Latest developments in radiopharmaceutical therapies

Ian A. Wilson, PhD, ImaginAb Inc., Los Angeles, CA, gives an overview of ongoing work in radiopharmaceutical therapies. Specifically discussed is the pairing of a CD8 antibody fragment with a radioisotope to produce targeted radiotherapy. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.